Altogether, these results lead us to propose FXYD5/Dys as a potential inflammation mediator in EC, facilitating monocyte recruitment to the tumor microenvironment and eventually promoting cancer progression, through NF-κB pathway activation. Here, FXYD5 is linked to cancer.